Available is now available OzemPIC and Wegovy through Goodrx at a reduced self -payment price, and Skyrockkets shares

Goodrx Holdings Inc. (Nasdak:GDRXI announced that through cooperation with Novo Nordisk A/S. (NYSE:Non -governmental organizations), All the strengths of OzemPIC (Semaglutide) and Wegovy (Semaglutide) pens are available to qualified patients to pay themselves for $ 499 a month through goodrx, An effective immediate.

Goodrx offers a platform for providing a drug in the United States

Cooperation greatly reduces the price available on GoodRX for two of the most requested requests GLP-1 Medicines in the countryExpanding access to those who do not have sufficient insurance coverage.

Also read: Goodrx offers value offer with pharmaceutical cost transformations for consumers: analysts

This step also represents the first time that OzemPIC has been provided for this self -paying price.

Last year, nearly 17 million people came to Goodrx in search of savings and information about the GLP-1 drugs, an increase of 22 % over the previous year.

Now, GoodRX is preparing to meet this increasing demand more effectively.

GoodRX research shows that 19 million people lack the coverage of the ING-1 weight loss. By filling the gaps in the coverage of insurance, Goodrx plays an important role in reducing friction in the system and helping to speed up the speed to treatment so that consumers can benefit from these important treatments.

Starting today, eligible patients can use GOODRX to self -payment for OzemPIC and Wegov pens for $ 499 a month in more than 70,000 pharmacists for retail levels in the country.

In March, Novo Nordisk provided Novocare Pharmacy, a direct delivery service to a patient to improve access to Wegovy for Patients who pay cash.

The program provides all the strengths of the dose in medicines to lose weight at a reduced price of $ 499 per month for unbelievable individuals or those who do not cover obesity treatments.

In June, Elie Lily and Partners (NYSE:ToIt announced that the highest doses are approved by Zepbound (Tirzepatide), 12.5 mg and 15 mg, will be available soon in one dose bottles for $ 499 per month through self -drive pharmacy solutions in Lillydirect and Zepbound Self -payment trip program.

Health care providers began describing a 12.5 mg vial and 15 mg on July 7; Shipping for patients It started in early August.

With the addition of these doses, each force will be available from the Zepbound vial for $ 499 per month or less ($ 349 for a 2.5 mg dose) for any adult qualified with obesity and a valid recipe, regardless of insurance.

after to updateand HIMS & HERS Health Inc (NYSE:ShakeThe shares are traded by 2.35 % at $ 44.94. In June, Novo Nordisk ended its cooperation with Hims & Rels Health.